Orchid Island Capital Announces First Quarter 2025 Results

About this update from Orchid Island Capital, Inc.

VERO BEACH, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended March 31, 2025. First Quarter 2025 Results Other Financial Highlights Management Commentary  Commenting on the first quarter results, Robert E. Cauley, Chairman and Chief Executive Officer, said, “The first quarter of 2025 was essentially a continuation of the fourth quarter of 2024, at least for the first two months or so.  While economic data and events generally are never uniformly stable or consistent, the first quarter of 2025 was relatively uneventful.  Interest rates were generally range bound, and volatility was low for most of the first quarter.  These are ideal conditions for a levered investment strategy in Agency RMBS.  Accordingly, the Company and the Agency RMBS market generated attractive returns for the period.  The Company’s stock also traded well during the quarter – at least until the last week of the quarter. The Company was able to take advantage of the calm conditions and price performance of its common stock during the first quarter to raise additional capital generally at a slight premium to book value and deploy the proceeds in an attractive investment environment. “In March of 2025 the Trump administration introduced the first of several tariffs.  The administration indicated there was more to come in the near future, and market expectations for growth and inflation began to erode quickly.  Sentiment was further depressed when some incoming economic data was consistent with stagflation – the combination of slowing economic growth and inflation. The tariff announcements late in the first quarter and in early April brought the favorable market conditions present through most of the first quarter of 2025 to an abrupt end.  In fact, conditions were reminiscent of March 2020 when the COVID-19 pandemic first emerged in the United States and led to a rapid de-leveraging that materially depressed prices of all asset classes. In early April, the Company sold assets as needed to maintain leverage at acceptable levels and was able to do so without suffering material permanent losses to date.  Since March 31, 2025, the portfolio was reduced by approximately 8% and book value declined by approximately 8.8% by April 17, 2025. It is not clear if these conditions have subsided fully or if they will return. Accordingly, the Company intends to maintain prudent leverage and ample liquidity while the threat of turbulent market conditions persists. Details of First Quarter 2025 Results of Operations The Company reported net income of $17.1 million for the three month period ended March 31, 2025, compared with net income of $19.8 million for the three month period ended March 31, 2024. Interest income on the portfolio in the first quarter was up approximately $9.1 million from the fourth quarter of 2024. The yield on our average Agency RMBS increased from 5.38% in the fourth quarter of 2024 to 5.41% for the first quarter of 2025, and our repurchase agreement borrowing costs decreased from 4.98% for the fourth quarter of 2024 to 4.29% for the first quarter of 2025. Book value decreased by $0.15 per share in the first quarter of 2025. The decrease in book value reflects our net income of $0.18 per share and the dividend distribution of $0.36 per share. The Company recorded net realized and unrealized gains of $1.6 million on Agency RMBS assets and derivative instruments, including net interest income on interest rate swaps. Prepayments For the quarter ended March 31, 2025, Orchid received $133.0 million in scheduled and unscheduled principal repayments and prepayments, which equated to a 3-month constant prepayment rate (“CPR”) of approximately 7.8%. Prepayment rates on the two RMBS sub-portfolios were as follows (in CPR): Portfolio The following tables summarize certain characteristics of Orchid’s PT RMBS (as defined below) and structured RMBS as of March 31, 2025 and December 31, 2024: Financing, Leverage and Liquidity As of March 31, 2025, the Company had outstanding repurchase obligations of approximately $6,418.6 million with a net weighted average borrowing rate of 4.46%. These agreements were collateralized by RMBS with a fair value, including accrued interest, of approximately $6,723.2 million and cash pledged to counterparties of approximately $2.8 million. The Company’s adjusted leverage ratio, defined as the balance of repurchase agreement liabilities divided by stockholders' equity, at March 31, 2025 was 7.5 to 1. At March 31, 2025, the Company’s liquidity was approximately $446.5 million consisting of cash and cash equivalents and unpledged RMBS. To enhance our liquidity even further, we may pledge more of our structured RMBS as part of a repurchase agreement funding, but retain the cash in lieu of acquiring additional assets.  In this way we can, at a modest cost, retain higher levels of cash on hand and decrease the likelihood we will have to sell assets in a distressed market in order to raise cash. Below is a list of our outstanding borrowings under repurchase obligations at March 31, 2025. Hedging In connection with its interest rate risk management strategy, the Company economically hedges a portion of the cost of its repurchase agreement funding against a rise in interest rates by entering into derivative financial instrument contracts. The Company has not elected hedging treatment under U.S. generally accepted accounting principles (“GAAP”) in order to align the accounting treatment of its derivative instruments with the treatment of its portfolio assets under the fair value option election. As such, all gains or losses on these instruments are reflected in earnings for all periods presented. At March 31, 2025, such instruments were comprised of U.S. Treasury note (“T-Note”) and Secured Overnight Financing Rate ("SOFR") futures contracts, interest rate swap agreements and contracts to sell to-be-announced ("TBA") securities. The table below presents information related to the Company’s T-Note and SOFR futures contracts at March 31, 2025. The table below presents information related to the Company’s interest rate swap positions at March 31, 2025. The following table summarizes our contracts to sell TBA securities as of March 31, 2025. Dividends In addition to other requirements that must be satisfied to qualify as a REIT, we must pay annual dividends to our stockholders of at least 90% of our REIT taxable income, determined without regard to the deduction for dividends paid and excluding any net capital gains. We intend to pay regular monthly dividends to our stockholders and have declared the following dividends since our February 2013 IPO. Book Value Per Share The Company's book value per share at March 31, 2025 was $7.94. The Company computes book value per share by dividing total stockholders' equity by the total number of shares outstanding of the Company's common stock. At March 31, 2025, the Company's stockholders' equity was $855.9 million with 107,786,614 shares of common stock outstanding. Capital Allocation and Return on Invested Capital The Company allocates capital to two RMBS sub-portfolios, the pass-through RMBS portfolio, consisting of mortgage pass-through certificates issued by Fannie Mae, Freddie Mac or Ginnie Mae (the “GSEs”) and collateralized mortgage obligations (“CMOs”) issued by the GSEs (“PT RMBS”), and the structured RMBS portfolio, consisting of interest-only (“IO”) and inverse interest-only (“IIO”) securities. As of March 31, 2025, approximately 97.9% of the Company’s investable capital (which consists of equity in pledged PT RMBS, available cash and unencumbered assets) was deployed in the PT RMBS portfolio. At December 31, 2024, the allocation to the PT RMBS portfolio was approximately 97.2%. The table below details the changes to the respective sub-portfolios during the quarter. The tables below present the allocation of capital between the respective portfolios at March 31, 2025 and December 31, 2024 and the return on invested capital for each sub-portfolio for the three month period ended March 31, 2025. The return on invested capital in the PT RMBS and structured RMBS portfolios was approximately 3.8% and 2.8%, respectively, for the first quarter of 2025. The combined portfolio generated a return on invested capital of approximately 3.8%. Stock Offerings On March 7, 2023, we entered into an equity distribution agreement (the “March 2023 Equity Distribution Agreement”) with three sales agents pursuant to which we could offer and sell, from time to time, up to an aggregate amount of $250,000,000 of shares of our common stock in transactions that were deemed to be “at the market” offerings and privately negotiated transactions. We issued a total of 24,675,497 shares under the March 2023 Equity Distribution Agreement for aggregate gross proceeds of approximately $228.8 million and net proceeds of approximately $225.0 million, after commissions and fees, prior to its termination in June 2024. On June 11, 2024, we entered into an equity distribution agreement (the “June 2024 Equity Distribution Agreement”) with three sales agents pursuant to which we could offer and sell, from time to time, up to an aggregate amount of $250,000,000 of shares of the our common stock in transactions that were deemed to be “at the market” offerings and privately negotiated transactions. We issued a total of 30,513,253 shares under the June 2024 Equity Distribution Agreement for aggregate gross proceeds of approximately $250.0 million and net proceeds of approximately $245.8 million, after commissions and fees, prior to its termination in February 2025. On February 24, 2025, we entered into an equity distribution agreement (the “February 2025 Equity Distribution Agreement”) with four sales agents pursuant to which we may offer and sell, from time to time, up to an aggregate amount of $350,000,000 of shares of our common stock in transactions that are deemed to be “at the market” offerings and privately negotiated transactions. Through March 31, 2025, we issued a total of 14,470,882 shares under the February 2025 Equity Distribution Agreement for aggregate gross proceeds of approximately $123.7 million, and net proceeds of approximately $121.7 million, after commissions and fees. Stock Repurchase Program On July 29, 2015, the Company’s Board of Directors authorized the repurchase of up to 400,000 shares of our common stock. The timing, manner, price and amount of any repurchases is determined by the Company in its discretion and is subject to economic and market conditions, stock price, applicable legal requirements and other factors. The authorization does not obligate the Company to acquire any particular amount of common stock and the program may be suspended or discontinued at the Company’s discretion without prior notice. On February 8, 2018, the Board of Directors approved an increase in the stock repurchase program for up to an additional 904,564 shares of the Company’s common stock. Coupled with the 156,751 shares remaining from the original 400,000 share authorization, the increased authorization brought the total authorization to 1,061,316 shares, representing 10% of the Company’s then outstanding share count. On December 9, 2021, the Board of Directors approved an increase in the number of shares of the Company’s common stock available in the stock repurchase program for up to an additional 3,372,399 shares, bringing the remaining authorization under the stock repurchase program to 3,539,861 shares, representing approximately 10% of the Company’s then outstanding shares of common stock. On October 12, 2022, the Board of Directors approved an increase in the number of shares of the Company’s common stock available in the stock repurchase program for up to an additional 4,300,000 shares, bringing the remaining authorization under the stock repurchase program to 6,183,601 shares, representing approximately 18% of the Company’s then outstanding shares of common stock. This stock repurchase program has no termination date. From the inception of the stock repurchase program through March 31, 2025, the Company repurchased a total of 5,144,602 shares at an aggregate cost of approximately $77.5 million, including commissions and fees, for a weighted average price of $15.07 per share. The Company did not repurchase any shares during the three months ended March 31, 2025. Subsequent to March 31, 2025, the Company repurchased a total of 1,113,224 shares at an aggregate cost of approximately $7.3 million, including commissions and fees, for a weighted average price of $6.52 per share. The remaining authorization under the stock repurchase program as of April 25, 2025 was 2,719,137 shares. Earnings Conference Call Details An earnings conference call and live audio webcast will be hosted Friday, April 25, 2025, at 10:00 AM ET. Participants can register and receive dial-in information at https://register-conf.media-server.com/register/BIa11531c18dc949b0a893a6a0aa5ee8a0. A live audio webcast of the conference call can be accessed at https://edge.media-server.com/mmc/p/9r3bcbth or via the investor relations section of the Company's website at https://ir.orchidislandcapital.com. An audio archive of the webcast will be available for 30 days after the call. About Orchid Island Capital, Inc. Orchid Island Capital, Inc. is a specialty finance company that invests on a leveraged basis in Agency RMBS. Our investment strategy focuses on, and our portfolio consists of, two categories of Agency RMBS: (i) traditional pass-through Agency RMBS, such as mortgage pass-through certificates, and CMOs issued by the GSEs, and (ii) structured Agency RMBS, such as IOs, IIOs and principal only securities, among other types of structured Agency RMBS. Orchid is managed by Bimini Advisors, LLC, a registered investment adviser with the Securities and Exchange Commission. Forward Looking Statements Statements herein relating to matters that are not historical facts, including, but not limited to statements regarding interest rates, inflation, liquidity, pledging of our structured RMBS, funding levels and spreads, prepayment speeds, portfolio composition, positioning and repositioning, hedging levels, leverage ratio, dividends, investment and return opportunities, the supply and demand for Agency RMBS and the performance of the Agency RMBS sector generally, the effect of actual or expected actions of the U.S. government, including the Fed, market expectations, capital raising, future opportunities and prospects of the Company, the stock repurchase program, geopolitical uncertainty and general economic conditions, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned that such forward-looking statements are based on information available at the time and on management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in such forward-looking statements. Important factors that could cause such differences are described in Orchid Island Capital, Inc.'s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Orchid Island Capital, Inc. assumes no obligation to update forward-looking statements to reflect subsequent results, changes in assumptions or changes in other factors affecting forward-looking statements. CONTACT: Orchid Island Capital, Inc. Robert E. Cauley, 772-231-1400 Chairman and Chief Executive Officer https://ir.orchidislandcapital.com Summarized Financial Statements The following is a summarized presentation of the unaudited balance sheets as of March 31, 2025, and December 31, 2024, and the unaudited quarterly statements of operations for the three months ended March 31, 2025 and 2024. Amounts presented are subject to change.

View stock analysis, news, and events for Orchid Island Capital, Inc.